

Research Article**Frequency of hepatitis B surface antigen and hepatitis C antibodies in patients presenting at DHQ Hospital, Okara**

¹Hashim sagheer, ²Mueed Ahmad
and ³Adnan Akram

¹Medical Officer DHQ Hospital Okara

²Medical Officer DHQ Hospital Okara

³Medical Officer BHU Sultanpur Hammar

ABSTRACT

Objective: To assess frequency of hepatitis B surface antigen and hepatitis C antibodies in patients presenting at DHQ Hospital, Okara.

Subjects & Methods: This cross sectional study was conducted at DHQ Hospital, Okara from January 2017 to June 2017. Total 16822 patients were selected during the study period. Frequency of hepatitis B surface antigen and hepatitis C antibodies in patients presenting at DHQ Hospital, Okara was assessed.

Results: A total of 16822 cases were referred in a year. Overall prevalence of HBsAg, Anti-HCV antibodies and co-infection (HBsAg + Anti-HCV) was 3.92%, 16.06% and 0.76% respectively. HBsAg positive in male patients in one year screening was 2.46% and female was 1.45% while Anti-HCV antibodies positive male in this population were 8.23% and females were 7.82%. Rate of co-infection positivity in males and females population was 0.45% and 0.30% respectively. Male to female ratio for HBsAg, Anti-HCV and co-infection was 1.5:1, 1:1.08 and 1.2:1 respectively. Both the genders were generally infected by HBsAg and HCV but the male patients were predominantly more infected with HBsAg and HCV antibodies.

Conclusion: High frequency of HBsAg and Anti-HCV positivity was due to biased population of hospitalized cases. Serious efforts need to be done to create awareness regarding HBsAg and Anti-HCV antibodies in all public and private hospitals and health clinics.

Keywords: Hepatitis B surface antigen, Hepatitis C virus, Co-infection

INTRODUCTION

Chronic hepatitis B and C infections are the major health issue worldwide and especially in Pakistan.¹ Hepatitis B virus was first isolated in 1963² and hepatitis C virus (HCV) was identified in 1989.³ Together, these two viral infections are the major cause of morbidity and mortality in the form of chronic liver disease, cirrhosis and hepatocellular carcinoma.⁴

Hepatitis B and C viruses pose a serious health problem around the globe.¹ Worldwide about 350 million people have chronic HBV infection;⁵ 170 million people have HCV and nearly 3-4 million people are newly infected each year.⁶ Pakistan

bears a huge burden of these viral diseases each year. A nation-wide survey carried out in 2007 and 2008 showed that the overall prevalence of HBV and HCV was 2.5% and 4.9% respectively. For HCV, the prevalence relative to provinces was 5% in Sindh, 6.7% in Punjab, 1.1% in KPK and 1.5% in Balochistan. For HBV infection, the figure were 2.5% in Sindh, 2.4% in Punjab, 1.3% in KPK and 4.3% in Balochistan.⁷ The common risk factors for disease transmission are blood transfusion, haemodialysis, thalassemia, use of blood contaminated syringes, frequenting a barber, tattooing and also by sexual

transmissions.⁸ Other studies conducted in the past report the prevalence of HBV around 3-10% and 2-14% for HCV.⁹⁻¹²

In general population HBV carrier rate has been reported up to 8-10% and HCV carrier rate around 6%.¹³⁻¹⁵ This is considered high compared to the extremely low prevalence rate of 0-1.5% in England and other Scandinavian countries, 0-1.6% in USA and Northern Europe, 0-1.9% in Southern Europe and a relatively higher prevalence of 1.7-5.2% in African countries.¹⁶⁻¹⁷

The main routes of transmission of both these viruses are parental. Although the seroprevalence among the general population has been documented, the disease still has a high prevalence in those seeking healthcare or admitted to hospitals. Present study was conducted to evaluate the frequency of HBV and HCV in patients referred from different wards and the out-patient department of Shaikh Zayed Hospital, Lahore for screening and confirmation purposes.

SUBJECTS AND METHODS

This cross sectional study was conducted at DHQ Hospital, Okara from January 2017 to June 2017.

Total 16822 patients were selected during the study period. Three millilitre of venous blood sample was collected from each patient, serum was separated and kept under refrigeration. The test was performed for HBsAg and Anti-HCV antibodies run with positive and negative control with each batch by ELISA (4th generation kit). All the results were documented.

RESULTS

There were 16822 samples of patients that were sent to the Microbiology department. Total males were 8871 (52.73%) and total female were 7951 (47.27%), In-patient were 8264 (49.10%) and out-patient were 8564 (50.90%). Overall frequency of HBV was 3.92%, Anti-HCV was 16.06% and co-infection with HBV and HCV was 0.76%. Total HB virus positive males were 2.46% and females were 1.45%. Male to female ratio was 1.5:1. Total Anti-HCV positive males were 8.24% and females were 7.82%. Male to female ratio was 1.1:1.08. In HBV and HCV co-infection, total male affected were 0.46% and females were 0.30%, male to female ratio was 1.2:1 (Tables 1-2).

Table 1: Frequency of genders (n = 16822)

Gender	No.	%
Male	8871	52.73
Female	7951	47.26

Table 2: Frequency of HBsAg, Anti-HCV and co-infection in different groups of patients

Gender	HCV +ve		HBsAg		Co-infection (B+C)	
	No.	%	No.	%	No.	%
Total	2703	16.06	660	3.92	129	0.76
Male	1385	15.63	415	4.67	78	0.87
Female	1317	16.58	245	3.08	51	0.64

DISCUSSION

Pakistan is highly endemic for Hepatitis B and C virus and Meta analysis of most of the studies presented in the meeting for formulation of guideline held in Karachi in 2003 put this in range of 4-25% depending on the population studied.¹⁸ According to the first national hepatitis survey conducted by NHRC, the prevalence of HBV and HCV in general population of Pakistan was well established.¹⁹ According to WHO survey, Pakistan

falls into the intermediate zone of infection for both hepatitis B and C virus.²⁰⁻²¹

The present study showed a high prevalence of hepatitis B at 3.92% and 16.06% for hepatitis C in patients referred from the out-patient and in-patient departments, high prevalence in various departments was due to bias selection of patients with a higher progression of disease visiting the hospital for consultation and admission as Shaikh Zayed Hospital is a tertiary care hospital and

patients are referred from all over the province and from various areas of the country.

In comparison, previous hospital based studies conducted in Pakistan showed hepatitis B prevalence at 5.9% and HCV at 12.8%.²² In other studies, HBsAg positivity was 3-5% and Anti-HCV was between 2-13.5%.^{23,24} In another study conducted in adult males, the frequency of HBsAg positive in Punjab was 3.7%, Sindh 5%, NWFP 1.8% and Balochistan and Azad Kashmir was 1.6% respectively. The frequency of Anti-HCV positive in Punjab was 1.9%, Sindh 4.1%, NWFP 0.9% and Balochistan 1.7%.²³ Other studies conducted in past report a prevalence between 3-10% of HBsAg and 2-14% of HCV antibodies.¹² In the present study, overall frequency of HBV & HCV positivity was compared to the other local studies mentioned above.²⁵

The prevalence of co-infection (HBV/HCV) in the National Survey was 0.1%¹⁹ and in PMRC study it was 1.1%²², where in this study it is 0.76% which is low compared to PMRC study but still high as compared to the national survey. These findings should be a matter of concern for healthcare providers and policy makers as the co-infection indicated in this study is more severe and difficult to treat, with high morbidity and mortality.

CONCLUSION

High frequency of HBV and HCV infection is due to a biased population of hospitalized cases. High frequency in this study indicates awareness and presence of highly specialized departments e.g. Gastrointestinal Department and Liver Transplant. Serious efforts are required about the awareness of the disease and its mode of transmission. Prevalence needs to be enhanced in all health care providers to curtail the spread of disease. Treatment is important to decrease the disease prevalence.

REFERENCES

1. Shah HN, Shabbir G. A review of published literature on hepatitis B & C prevalence in Pakistan. *J Coll Physicians Surg Pak* 2002; 12: 368-71.

2. Blumberg BS. Australia antigen and the biology of hepatitis B. *Science* 1977; 197: 17-25.
3. Kuo G, Choo QL, Alter HJ, Gitnick GL, Redekar AG, Purcell RH, et al. An assay for circulating antibodies to a major etiologic virus of human non-A non-B hepatitis. *Science* 1989; 21: 362-4.
4. Cusher A. Acute and chronic viral hepatitis. In: Chsheri A, Steele JC, Mossa AR, editors. *Essential surgical practice*. 5th ed. Oxford: 2002, pp, 334-5.
5. WHO. Hepatitis B. Fact sheet N° 204. Revised August 2008. Available from: URL: [http://www.who.int/medicentre/factsheets/fs204/ne/] Assessed on April 10, 2009.
6. IDENEX PHARMACEUTICALS - HEPATITIS FACT SHEET 10/06. Available from: URL www.idenix.com/hepc/fact/Idenix_HCV_Background.pdf. Accessed on April 10, 2009.
7. Qureshi H, Bile KM, Jooma R, Alam SE, Afridi HUR. Prevalence of hepatitis B and C viral infection in Pakistan: findings of a national survey appealing for effective prevention and control measures. *Eastern Mediterr Health J* 2010; 16 (supp): S15-23.
8. Luby S. The relationship between therapeutic infections and high prevalence of Hepatitis C infection in Hafizabad, Pakistan. *Epidemiol infect* 1997; 119: 349-56.
9. Zuberi SJ. An overview of HBV/HCV in Pakistan. *Pakistan J Med Res* 1998; 37; S12.
10. Mujeeb SA, Amir K, Mehmood K. Seroprevalence of HBV, HCV and HIV infection among college going first time voluntary blood donors. *J Pak Med Assoc* 2000; 50: 269-70.
11. Asif N, Khokar N, Ilahi F. Seroprevalence of HBV, HCV and HIV infection among voluntary non-remunerated and replacement donors in Northern Pakistan. *Pak J Med Sci* 2004; 20: 24-8.
12. Khokar N, Gill ML, Malik GJ. General seroprevalence of hepatitis C and hepatitis B

- virus infection in population. *J Coll Physicians Surg Pak* 2004; 14: 534-6.
13. Zuberi SJ, Lodhi TZ, Samad F. Prevalence of HBsAg and antibody in healthy subjects and patients with liver disease. *J Pak Med Assoc* 1978; 28: 2-3.
 14. Muhammad N, Jan AM. Frequency of hepatitis C infection in District Bunir (NWFP). *J Coll Physicians Surg Pak* 2005; 15: 11-4.
 15. Khan H, Khan N, Niazi R, Adam T, Yaqoob A. Seroprevalence of hepatitis C in Pakistanis visiting and admitted at the Pakistan Institute of Medical Sciences, Islamabad. *J Surg* 2001; 21: 22-6.
 16. Estaban JI, Estaban R. Hepatitis C virus antibodies among risk group in Spain. *Lancet* 1989; 11: 297-8.
 17. Anonymous. Prevalence of hepatitis C antibody carrier in blood donors. *Hepatology* 1992; 16: 547-8.
 18. Zuberi Z. Hepatitis B: Pakistani perspective; National Consensus conference on guidelines for hepatitis B and C, Karachi, August 2003.
 19. PMRC. Prevalence of hepatitis B & C in Pakistan, Islamabad. Pakistan Medical Research Council, 2008.
 20. Lok AS, McMahon BJ. Chronic hepatitis B. *Hepatology* 2007; 45: 507-39.
 21. WHO. *Wkly Epidemiology Rec* 2002; 77: 41.
 22. Khan RAW, Ahmed W, Alam SE, Arif A. Screening of HBsAG and anti HCV from tertiary care, private and public sector hospitals. *Pak J Med Res* 2011; 50(1): 20-23.
 23. Butt T, Amin MS. Seroprevalence of hepatitis B and C infections among young adult males in Pakistan. *Eastern Mediterr Health J* 2008; 14: 791-7.
 24. Waheed Y, Shafi T, Safi SZ, Qadri I. Hepatitis C virus in Pakistan: a systematic review of prevalence, genotypes and risk factors. *World J Gastroenterol* 2009; 15: 5647-53.
 25. Abbas Z, Shazi L, Jafri W. Prevalence of hepatitis B in individuals screened during a country wide. *J Coll Physicians Surg Pak* 2006; 16: 495.